CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Fremanezumab

Fremanezumab

In September 2018, Ajovy (fremanezumab) became the second CGRP monoclonal antibody to be approved for the prevention of migraine in adults, and the first and only anti-CGRP therapy with monthly and quarterly dosing options. Approval was supported by data including results of two large Phase 3 clinical trials, one in episodic migraine and the other in chronic migraine. The subsequent Phase 3b FOCUS trial investigated fremanezumab in patients with an inadequate response to 2-4 previous preventive therapies.


Download slideset »


« back to Slides